titioner's Docket No. MWH-0029US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Stephen Bryant Liggett

Group No.: 1634

Application No.: 09/856,803

I.A. Filing Date: November 24, 1999

Examiner: Carla J. Myers

I.A. No.:

PCT/US99/27963

For: Polymorphisms in the 5' Leader Cistron of the Beta 2 Adrenergic Receptor

Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

TIME OF TRANSMITTAL OF ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

- The information disclosure statement transmitted herewith is being filed after three months of the 1. filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but before the mailing date of either
 - (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311

whichever occurs first.

CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

G deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington D.C. 20231 37 C.F.R. § 1.10* 37 C.F.R. § 1.8(a) G as "Express Mail Post Office to Addressee"

G with sufficient postage as first class mail.

(mandatory) Mailing Label No. E 533974842

TRANSMISSION

G facsimile transmitted to the Patent and Trademark Office, (703)

Signature

(type or print name of person certify

* Only the date of filing (' 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under ' 1.8 continues to be taken into account in determining timeliness. See ' 1.703(f). Consider "Express Mail Post Office to Addressee" (' 1.10) or facsimile transmission (' 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

04/22/2003 MDANTE1 00000079 501293 Transmittal of Information Disclosure Statement before Mailing Date of Either a Final Action Or Notice of Allowance--page 1 of 2 © 2002 Matthew Bender & Company, Inc., a member of the LexisNexis Group.

180.00 CH

FEE

2. Accompanying this transmittal is the fee for submission of an information disclosure statement under section 1.97(c). (\$180.00)

FEE PAYMENT

3. Applicant elects the option to pay the fee set forth in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under § 1.97(c) (\$180.00).

Fee due \$180.00

METHOD OF PAYMENT OF FEE

4. Authorization is hereby made to charge the amount of \$180.00 to Deposit Account No. 50-1293.

Charge any additional fees required by this paper or credit any overpayment in the manner authorized above.

A duplicate of this paper is attached.

Date: 4/15/2003

Reg. No.: 37,848

Tel. No.: 203-786-3421

Melodie W. Henderson

Genaissance Pharmaceuticals, Inc.

Melvolie W. Venderson

5 Science Park

New Haven, CT 06511

Customer No. 25106

PTO/SB/08A (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	09/856,803		
Filing Date	05/25/2001		
First Named Inventor	Stephen Bryant Liggett		
Art Unit	1634		
Examiner Name	Carla J. Myers		
Attorney Docket Number	M/A/H_002QLIS		

	U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	 		00/05/00				
	CA	^{US-} 09/954,292	02/27/03	Drysdale et al.	Entire Document		
		US-					
		US-					
***		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		U\$-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
	†	US-					

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Ι.
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	·	Or Relevant Figures Appear	T
						_
						╀
	<u></u>					╀
	<u> </u>			·		\vdash
	 					\vdash

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.